Trazodone Label Tightens Safety Focus Across Mood, Cardiac, and Neurologic Risks
Trazodone hydrochloride remains labeled for the treatment of major depressive disorder, but the current prescribing information reads like a reminder that antidepressant selection is rarely a single-variable decision. The drug is available as scored 50 mg, 100 mg, 150 mg, and 300 mg tablets, with dosing that begins at 150 mg per day in divided doses and can be increased by 50 mg per day every three to four days to a maximum of 400 mg per day in divided doses. Tablets are intended to be swallowed whole or broken along the score line, not chewed or crushed, and administration shortly after a meal or light snack is recommended.
A dose change this modest can still produce a large bedside effect when sedation, orthostasis, and drug interactions are in play.
Boxed Warning and the Need for Early Monitoring
The boxed warning centers on suicidal thoughts and behaviors in pediatric and young adult patients. Antidepressants increase that risk, and the label directs clinicians to monitor closely for clinical worsening as well as emergent suicidal ideation or behavior. Trazodone is not approved for pediatric use, which places the warning in a broader context of age-specific risk rather than routine extrapolation from adult depressive disease.
In practical terms, the warning affects more than diagnosis. It shapes follow-up cadence, family counseling, and the threshold for reassessing treatment when mood shifts early in therapy. The drug’s antidepressant benefit does not erase the need for vigilance during initiation, dose escalation, or discontinuation.
Serotonergic Toxicity, QT Prolongation, and the Cardiac Bedside
The labeling places substantial emphasis on serotonin syndrome. Risk rises when trazodone is combined with other serotonergic agents such as SSRIs, SNRIs, or triptans, but the syndrome can also occur when trazodone is used alone. When it appears, treatment requires immediate discontinuation and supportive care. This reflects the pharmacology of serotonin excess, where neuromuscular excitation, autonomic instability, and mental status changes can escalate quickly if the culprit drug remains on board.
Cardiac risk receives similar attention. Trazodone increases the QT interval, and use should be avoided with other QT-prolonging drugs and in patients with risk factors for prolonged QT. For patients with baseline arrhythmia vulnerability, electrolyte abnormalities, structural heart disease, or polypharmacy, the label effectively turns a routine antidepressant choice into a cardiac safety decision.
Orthostatic hypotension and syncope sit close to that same hazard cluster. The pressure-lowering effect can be especially relevant in older adults or in anyone already prone to falls, dehydration, or autonomic instability. The prescribing information also flags cognitive and motor impairment, a practical warning for patients who drive, operate machinery, or already take other sedating medications.
Bleeding, Priapism, Mania, and Eye Pressure Risks
Beyond the central nervous system and the heart, trazodone carries warnings that are easy to miss if the label is read too narrowly. Concomitant use with aspirin, NSAIDs, antiplatelet therapy, warfarin, or other anticoagulants may increase the risk of bleeding. The mechanism is clinically relevant because serotonin signaling participates in platelet function, and inhibition of serotonin reuptake can weaken hemostatic reserve.
Priapism remains a rare but serious labeled adverse effect, with painful and prolonged penile erections requiring immediate medical attention. The warning is short, but the clinical consequence is not: delayed response can threaten erectile function and tissue viability.
Screening for bipolar disorder matters because trazodone can activate mania or hypomania. The label also warns against use in patients with untreated anatomically narrow angles because antidepressants, including trazodone, can precipitate angle-closure glaucoma. In these settings, psychiatric treatment and ocular anatomy are linked by the same autonomic pharmacology.
Discontinuation, Hyponatremia, and Common Adverse Effects
When trazodone is stopped, gradual dose reduction is recommended. Abrupt withdrawal can trigger discontinuation symptoms, which is why tapering is built into the label rather than left to individual habit. The warning is especially relevant for patients who have taken the medication longer term or at higher doses.
Hyponatremia appears among the labeled precautions as well, another reminder that serotonergic antidepressants can affect fluid and electrolyte balance in vulnerable patients. In older adults, fatigue, confusion, or unsteadiness may be the first clues.
The most common adverse reactions, occurring in at least 5% of patients and at twice the placebo rate, are edema, blurred vision, syncope, drowsiness, fatigue, diarrhea, nasal congestion, and weight loss. Several of these effects point in the same direction: sedation, vasodilation, and tolerability problems that can complicate adherence even when mood symptoms improve.
Drug Interactions Define Much of the Real-World Risk
The interaction section is as important as the indication. Trazodone can enhance the effects of alcohol, barbiturates, and other CNS depressants. Strong CYP3A4 inhibitors may require dose reduction based on tolerability, while strong CYP3A4 inducers may require a dose increase. The label also calls for monitoring when trazodone is combined with digoxin or phenytoin because serum levels may rise, and warfarin therapy can become less predictable with either increased or decreased prothrombin time.
Those details matter because trazodone is often prescribed in patients who already carry substantial medication burden. One prescription can influence sedation, coagulation, arrhythmia risk, and neurologic function at the same time.
Specific Populations and the Limits of Extrapolation
The label includes separate guidance for pregnancy, lactation, pediatric use, geriatric use, renal impairment, and hepatic impairment. Even without numerical subgroup data in the reporting text, the structure of the prescribing information makes the clinical message plain: trazodone requires caution when physiology changes drug handling or amplifies adverse effects.
The revised labeling date is October 11, 2026, and the package is listed as a repackaged human prescription drug under abbreviated new drug application status. The clinical bottom line rests less on novelty than on restraint: trazodone can be effective for major depressive disorder, but its use demands attention to suicidality, serotonin toxicity, orthostasis, QT prolongation, bleeding risk, and interactions that can change the drug’s profile quickly at the bedside.